title: A comprehensive company database analysis of biological assay variability.
abstract: Analysis of data from various compounds measured in diverse biological assays is a central part of drug discovery research projects. However, no systematic overview of the variability in biological assays has been published and judgments on assay quality and robustness of data are often based on personal belief and experience within the drug discovery community. To address this we performed a reproducibility analysis of all biological assays at AstraZeneca between 2005 and 2014. We found an average experimental uncertainty of less than a twofold difference and no technologies or assay types had higher variability than others. This work suggests that robust data can be obtained from the most commonly applied biological assays.
authors.affiliation: Department of Theoretical Chemistry, Faculty for Chemistry and Pharmacy, Center for Molecular Biosciences Innsbruck (CMBI), Leopold-Franzens University Innsbruck, Innrain 80/82, A-6020 Innsbruck, Austria.
authors.forename: Christian
authors.initials: C
authors.lastname: Kramer
authors.affiliation: Department of Stucture and Biophysics, Discovery Sciences, AstraZeneca R&D, Pepparedsleden 1, S-431 83 Mölndal, Sweden. Electronic address: goran.dahl@astrazencea.com.
authors.forename: Göran
authors.initials: G
authors.lastname: Dahl
authors.affiliation: Department of Medicinal Chemistry, RIA iMed, AstraZeneca R&D, Pepparedsleden 1, S-431 83 Mölndal, Sweden.
authors.forename: Christian
authors.initials: C
authors.lastname: Tyrchan
authors.affiliation: Department of Medicinal Chemistry, CVMD iMed, AstraZeneca R&D, Pepparedsleden 1, S-431 83 Mölndal, Sweden.
authors.forename: Johan
authors.initials: J
authors.lastname: Ulander
mesh_terms: D001681:Biological Assay / Q000706:statistics & numerical data*; D016208:Databases, Factual; D004345:Drug Industry; D015203:Reproducibility of Results; D035501:Uncertainty